NCT03157128 2026-04-16LIBRETTO-001Eli Lilly and CompanyPhase 1/2 Active not recruiting857 enrolled 24 charts 6 FDA
NCT03155620 2026-04-14Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting1,377 enrolled 10 charts
NCT04268550 2026-03-23Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)SWOG Cancer Research NetworkPhase 2 Active not recruiting124 enrolled
NCT04211337 2026-03-19LIBRETTO-531Eli Lilly and CompanyPhase 3 Active not recruiting291 enrolled 16 charts 2 FDA